Prevention of cardiovascular events – in which patients to use combinations of rosuvastatin with ezetimibe? Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
rosuvastatin, ezetimibe, hypercholesterolemia, lipid disorders, combined therapy, cardiovascular risk
Main Article Content
Abstract
Lipid metabolism disorders affect more than 60% of the population. Given the undeniably proven adverse effects of elevated lipid concentrations on cardiovascular disease risk, early, effective and safe hypolipemic therapy is necessary. In patients with baseline high cholesterol concentrations and at high cardiovascular risk, pharmacological intervention should be characterized by high potency. Therefore, patients requiring a > 50% reduction in LDL-cholesterol levels should receive combined hypolipemic therapy at the outset.
Article Details
How to Cite
Łukasiewicz, M., & Mamcarz, A. (2024). Prevention of cardiovascular events – in which patients to use combinations of rosuvastatin with ezetimibe?. Medycyna Faktow (J EBM), 17(1(62), 29-32. https://doi.org/10.24292/01.MF.0124.04
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gajewski P (ed). Interna Szczeklika. Medycyna Praktyczna, Kraków 2023.
2. Pirillo A, Casula M, Olmastroni E et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021; 18(10): 689-700.
3. Rywik S, Broda G, Piotrowski W et al. Epidemiologia chorób układu krążenia – Program Pol-MONICA Warszawa. Kardiol Pol. 1996; 44(suppl 2): 7-35.
4. Studziński K, Tomasik T, Windak A et al.; On Behalf Of The Lipidogram Investigators. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. J Clin Med. 2021; 10(23): 5656.
5. Banach M, Burchardt P, Chlebus K et al. Wytyczne PTL/KLRwP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. Lekarz POZ. 2021; 4: 1-111.
6. Szymański FM, Mickiewicz A, Dzida G et al. Leczenie dyslipidemii w Polsce – interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. IV Deklaracja Sopocka. Choroby Serca i Naczyń. 2021; 18(3): 95-120.
7. Visseren FLJ, Mach F, Smulders YM et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
8. Katzmann JL, Sorio-Vilela F, Dornstauder E et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: Effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022; 111: 243-52.
2. Pirillo A, Casula M, Olmastroni E et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021; 18(10): 689-700.
3. Rywik S, Broda G, Piotrowski W et al. Epidemiologia chorób układu krążenia – Program Pol-MONICA Warszawa. Kardiol Pol. 1996; 44(suppl 2): 7-35.
4. Studziński K, Tomasik T, Windak A et al.; On Behalf Of The Lipidogram Investigators. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. J Clin Med. 2021; 10(23): 5656.
5. Banach M, Burchardt P, Chlebus K et al. Wytyczne PTL/KLRwP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. Lekarz POZ. 2021; 4: 1-111.
6. Szymański FM, Mickiewicz A, Dzida G et al. Leczenie dyslipidemii w Polsce – interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. IV Deklaracja Sopocka. Choroby Serca i Naczyń. 2021; 18(3): 95-120.
7. Visseren FLJ, Mach F, Smulders YM et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
8. Katzmann JL, Sorio-Vilela F, Dornstauder E et al. Non-statin lipid-lowering therapy over time in very-high-risk patients: Effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2022; 111: 243-52.